Jun 25, 2024
Braeburn Announces Publication of a Post Hoc Analysis of Data from Patients Using Fentanyl Treated with BRIXADI in a Phase 3 Efficacy and Safety Study
Jun 01, 2020
Braeburn Submits Request for Final Approval of BRIXADI(TM) (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Nov 07, 2019
Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi(TM) From the US market
Jul 23, 2019
U.S. District Court Orders FDA to Reconsider Application for Final Approval of BRIXADI(TM) (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Apr 09, 2019
Citizen Petition Calls on FDA to Revoke Orphan Designation for Sublocade
Apr 06, 2019
Positive Treatment Results for BRIXADI(TM) (buprenorphine) Extended-Release Injection in Fentanyl Positive Patients Presented at the 50th Conference of the American Society of Addiction Medicine
Dec 23, 2018
Braeburn Announces Tentative FDA Approval of BRIXADI(TM) (buprenorphine) Extended-Release Injection for the Treatment of Moderate to Severe Opioid Use Disorder
Sep 21, 2018
CAM2038 Receives Positive CHMP Opinion for the Treatment of Opioid Dependence in Europe
Sep 18, 2018
Braeburn Announces Positive Top-line Phase 3 Results for CAM2038 in Chronic Low Back Pain Patients Previously on Long-term Daily Opioid Therapy
Jul 16, 2018
Braeburn Announces PDUFA Date for CAM2038 for the Treatment of Opioid Use Disorder
Jun 25, 2018
Braeburn Appoints Richard Malamut, M.D. as Chief Medical Officer
May 30, 2018
Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence
May 28, 2018
Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder
Apr 12, 2018
Braeburn Launches Brave Action
Jun 05, 2017
Braeburn Pharmaceuticals Names Michael M. Derkacz as President and CEO